Development asset linked to Bicara Therapeutics in public FDA and regional records.
pharma · Head and Neck Squamous Cell Carcinoma · Metastatic Head and Neck Squamous Cell Carcinoma · BCAX
Bicara Therapeutics
Bicara Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Boston, USA HQ
2020 Founded
115 Employees
Public company Type
BCAX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2020
- Employees
- 115
- Programs
- 6
- Drugs
- 4
- Patents
- 0
Bicara Therapeutics pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Bicara Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Bicara Therapeutics in public FDA and regional records.
-
Development asset linked to Bicara Therapeutics in public FDA and regional records.